Home / Health / AstraZeneca turns to Covid-19 Vaccine Data Report due July 20th

AstraZeneca turns to Covid-19 Vaccine Data Report due July 20th



AZN) lost almost 5% in aftermarket trading in the middle of a report that early-stage data from human trials on the drug manufacturer’s coronavirus vaccine candidate will be revealed on July 20. “data-reactid =” 12 “> Shares in AstraZeneca (AZN) lost almost 5% in aftermarket trading in the middle of a report that early-stage data from human trials on the drug manufacturer̵

7;s coronavirus vaccine candidate will be revealed on July 20.

The stock rose to $ 60.60 in Wednesday’s expanded trading after jumping 7% earlier. Data from the Phase 1 study of the potential coronavirus vaccine, also known as AZD1222, which AstraZeneca is developing with Oxford University, are scheduled to be published on Monday, according to the Lancet medical journal.

The data are expected to show whether the potential vaccine is safe and whether it triggers an immune response or not. Earlier this month, vaccine developers said they were encouraged by the immune response they had seen in studies so far.

“We expect this paper, which is undergoing final editing and preparation, to be published on Monday, July 20 for immediate release,” a spokeswoman for the magazine told Reuters.

At the same time, the vaccine candidate is already in large-scale phase III human studies to assess whether it can protect against COVID-19.

In recent weeks, AstraZeneca has signed an agreement on the supply chain for the capacity to produce 2 billion doses of its vaccine candidate. The British drug manufacturer has delivered supply agreements with the USA and EU countries.

AZD1222 is one of several candidates supported by Operation Warp Speed ​​(OWS), the US government program to accelerate the development, manufacture and distribution of COVID-19 vaccines available to Americans in January 2021.

See AstraZeneca stock analysis on TipRanks) “data-reactid =” 19 “> Shares have jumped 53% since mid-March when AstraZeneca joined the list of companies involved in the development of a potential coronavirus vaccine. Despite the recent rally, the average analytical price target for 61 , $ 67 still up 6.3% potential over the next 12 months (see AstraZeneca stock analysis on TipRanks)

Strong buy consensus from the analyst community based on four unanimous purchase ratings. “data-reactid =” 20 “> Overall, the stock receives a strong buying consensus from the analyst community based on four unanimous purchase ratings.

AstraZenecas wins FDA Priority Review for heart medicine Brilinta
Novavax Spikes 42% pre-market on $ 1.6B US funding for Covid-19 candidates
Are Modern (MRNA) stocks still worth buying after its huge rally? JPMorgan says yes“data-reactid =” 29 “> Related News:
AstraZenecas wins FDA Priority Review for heart medicine Brilinta
Novavax Spikes 42% pre-market on $ 1.6B US funding for Covid-19 candidates
Are Modern (MRNA) stocks still worth buying after its huge rally? JPMorgan says yes

Newer articles from Smarter Analyst:


Source link